As part of Osgoode’s IP Law and Technology Intensive Program, I had the amazing opportunity to serve a 10-week internship at AstraZeneca Canada under the supervision of AstraZeneca’s Legal Director,…
Tag: AstraZeneca
IP Intensive: AstraZeneca visits the Supreme Court of Canada
As part of Osgoode’s Intellectual Property Law & Technology Intensive Program, I had the distinct pleasure of working with the Legal Affairs team at AstraZeneca Canada. With a technical background…
IP Intensive: A Semester at AstraZeneca Canada
Last semester, as part of Osgoode’s Intellectual Property Law and Technology Intensive Program, I had the opportunity to work with in-house counsel at AstraZeneca Canada. Having previously completed graduate studies…
An Unexpected Infringement: There and Back Again
On March 16, 2015, Justice Barnes held that AstraZeneca’s Patent No 1,292,693 (“’693 Patent”), a formulation patent for omeprazole, was valid and infringed by Apotex (2015 FC 322). This decision…
Apotex Successfully Invalidates Patent on Nexium
AstraZeneca has been selling Nexium in Canada for 13 years. It is prescribed to treat ulcers, gastroesophageal reflux disease (GERD) and related diseases. The active ingredient in Nexium is esomeprazole,…